Drug Safety in Nigeria

Medicines and medical products are authorised because their expected benefits outweigh known and potential risks for the intended population and use. That balance can change as exposure grows, rare events emerge, use expands, or product-quality problems occur. Drug safety, or pharmacovigilance, is the continuous detection, assessment, understanding, and prevention of adverse effects and other medicine-related problems.¹

For companies operating in Nigeria, this discipline is not only a quality function. It is a practical way to protect patients, strengthen regulatory compliance, and preserve trust with health authorities, healthcare professionals, and the public. Good drug safety practices connect closely with pharmacovigilance services, adverse drug reaction reporting, regulatory consulting, and medical information processes.

Report suspicion early rather than waiting for proof

An adverse-event report does not establish that a medicine caused the event. It provides information that can be assessed alongside other evidence. Delaying a report until causality is certain can prevent regulators and companies from seeing an important pattern.

Healthcare professionals and patients should provide as much information as is available, including an identifiable patient, an identifiable reporter, the suspected product, and the suspected reaction. Follow-up information such as timing of exposure and event, dose and indication, medical history, concomitant products, investigations, treatment, outcome, dechallenge or rechallenge information, and batch details can be very important. Patient privacy should be protected at every stage.

Know what belongs in the safety pathway

Nigeria’s 2024 adverse-reaction reporting guideline describes a broad surveillance scope that includes adverse drug reactions, lack of efficacy, interactions, overdose, misuse, medication errors, off-label use, substandard or falsified medicines, and medical-device incidents.² Product complaints and treatment failure may therefore require both quality and safety review.

NAFDAC also launched an improved Med Safety App in June 2026 to allow healthcare professionals and the public to report suspected adverse drug reactions and suspected substandard or falsified medical products.³ Organisations should document the route used for each report and retain evidence of submission, because reporting channels and reporting expectations can change over time.

Effective safety oversight is also built around Good Pharmacovigilance Practice and a documented Risk Management Plan.

What happens after receipt

A drug-safety team validates the report, checks for duplicates, assesses seriousness and expectedness, codes the medical information, seeks clinically relevant follow-up, conducts medical review, and submits the report within applicable timelines. It should preserve the reporter’s account while clearly separating reported facts from company assessment.

Reporting rules depend on the source and category. NAFDAC’s 2021 Good Pharmacovigilance Practice guideline includes a 15-calendar-day requirement for serious adverse reactions and specifies 15-day handling for certain important situations, including selected reports of lack of therapeutic efficacy and suspected transmission of an infectious agent.⁴ The certificate holder should maintain a current reporting matrix rather than rely on memory.

A case is not the same as a signal

A signal is information suggesting a new potentially causal association, or a new aspect of a known association, that warrants further investigation. One well-documented case can be important, while a large number of poorly characterised reports may remain difficult to interpret. Signal assessment considers clinical plausibility, time to onset, dechallenge or rechallenge, alternative causes, reporting patterns, exposure, literature, class effects, trials, observational data, and product quality.

ICH E2E recommends planned pharmacovigilance based on important identified and potential risks and missing information.⁵ Signal review should lead to a documented conclusion: close with justification, continue monitoring, investigate further, update aggregate assessment, communicate risk, change product information, introduce risk-minimisation measures, conduct a study, or take urgent action.

Connect safety with quality and public-health action

Safety reports may indicate a batch defect, storage problem, falsification, medication-use error, or inadequate risk communication. Pharmacovigilance, quality, medical, regulatory, and supply teams should have a rapid cross-functional escalation route. NAFDAC’s recall guidance allows action when quality, safety, or efficacy concerns justify withdrawal or recall.⁶

Risk communication should be accurate, timely, proportionate, and consistent with regulatory decisions. It should explain the concern, affected product or population, recommended action, and reporting route without creating unsupported reassurance or alarm.

Make reporting easier

Health facilities and companies can improve reporting by training staff on what to report, placing clear reporting instructions at points of care, acknowledging reporters, protecting confidentiality, reviewing errors without blame, and giving feedback on resulting action. Companies should reconcile reports across medical information, quality complaints, distributors, patient programmes, digital channels, and studies.

The purpose of drug-safety reporting is not to assign fault. It is to turn real-world experience into earlier detection, better evidence, and safer use of medical products. For organisations building strong systems, our Resources hub, the NAFDAC Compliance Checklist, and tailored training and consulting can help structure the next steps.

References

1. World Health Organization. Pharmacovigilance. Accessed July 18, 2026. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance
2. National Agency for Food and Drug Administration and Control. Nigerian guidelines for detecting and reporting adverse reactions for pharmaceutical products and medical devices. Effective October 14, 2024. Accessed July 18, 2026. https://nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/Nigerian-Guidelines-for-Detecting-and-Reporting-of-Adverse-Reactions-for-Pharmaceutical-Products-and-Medical-Devices.pdf
3. National Agency for Food and Drug Administration and Control. NAFDAC launches improved Med Safety App to strengthen reporting of substandard and falsified medical products and adverse drug reactions in Nigeria. Published June 2, 2026. Accessed July 18, 2026. https://nafdac.gov.ng/nafdac-launches-improved-med-safety-app-to-strengthen-reporting-of-substandard-and-falsified-medical-products-and-adverse-drug-reactions-in-nigeria/
4. National Agency for Food and Drug Administration and Control. Good pharmacovigilance practice guidelines. Effective January 21, 2021. Accessed July 18, 2026. https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PVG_GUIDELINES/NAFDAC-Guidelines-on-Good-Pharmacovigilance-2021.pdf
5. International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. ICH E2E: Pharmacovigilance planning. Published November 18, 2004. Accessed July 18, 2026. https://database.ich.org/sites/default/files/E2E_Guideline.pdf
6. National Agency for Food and Drug Administration and Control. Guidelines for the recall of defective medical products. Effective September 30, 2024. Accessed July 18, 2026. https://www.nafdac.gov.ng/wp-content/uploads/Files/Resources/Guidelines/PMS_Guidelines_2024/NAFDAC-Guidelines-for-the-Recall-of-Defective-Medical-Products.pdf